Clinical Trials
3 trialsNCT06102525 2025-09-05
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
Rznomics, Inc.
Phase 1/2 Recruiting
NCT03397706 2025-03-20
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
Viracta Therapeutics, Inc.
Phase 1/2 Completed
NCT00478465 2022-05-27
Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
Stanford University
Phase 1/2 Completed